PAVmed Restructures Capital With New Preferred Financing

PAVmed ( (PAVM) ) has issued an update.

On February 3, 2026, PAVmed raised $30 million through the issuance of newly designated Series D Convertible Preferred Stock to accredited investors, together with warrants that could provide up to an additional $30 million in preferred equity upon certain conditions, and simultaneously issued a new $15 million senior secured note maturing in February 2029 to an existing investor. Using the proceeds, the company redeemed all outstanding Series C Convertible Preferred Stock and refinanced and fully retired its prior convertible debt, leaving approximately $7.7 million in net cash for working capital, and positioning its capital structure to consist primarily of common equity and long-term debt once the Series D converts, subject to stockholder approval at a special meeting expected by April 30, 2026. PAVmed has secured voting commitments from holders of roughly a quarter of its common stock in favor of the conversion proposal, and management framed the transaction as a transformational clean-up of a longstanding capital structure overhang that strengthens the balance sheet, clarifies ownership ahead of anticipated value catalysts at Lucid Diagnostics and Veris Health, and enhances the company’s flexibility to pursue additional commercial opportunities while it continues to hold 31 million Lucid shares on its balance sheet.

The most recent analyst rating on (PAVM) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Spark’s Take on PAVM Stock

According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.

The score is held down primarily by weak financial performance (persistent losses and negative cash flows). Offsetting factors include somewhat improved near-term technical stabilization and a more constructive earnings update (Medicare progress and extended runway), while valuation remains constrained by unprofitability and listing-related events add residual risk.

To see Spark’s full report on PAVM stock, click here.

More about PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating across the medical device, diagnostics and digital health sectors. Its key subsidiaries include Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company marketing the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer, and Veris Health, a digital health business developing a remote patient monitoring platform for personalized cancer care, including an implantable physiological monitor designed to work alongside chemotherapy ports.

Average Trading Volume: 991,154

Technical Sentiment Signal: Strong Sell

Current Market Cap: $9.94M

Find detailed analytics on PAVM stock on TipRanks’ Stock Analysis page.